利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

110 条记录 (耗时 0.033 秒)

    IKK-BETA PROTEINS, NUCLEIC ACIDS AND METHODS
    4.
    发明授权
    IKK-BETA PROTEINS, NUCLEIC ACIDS AND METHODS 失效
    IKK-β蛋白质，核酸和程序

    公开(公告)号：EP1005540B1

    公开(公告)日：2004-06-16

    申请号：EP98933095.6

    申请日：1998-07-01

    申请人： Tularik Inc.

    发明人： GOEDDEL, David, V. ,  WORONICZ, John

    IPC分类号： C12N9/12 ,  G01N33/50

    CPC分类号： C12N9/1205 ,  A61K38/00

    摘要： The invention provides methods and compositions relating to an IλB kinase, IKK-β, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKK-β encoding nucleic acids or purified from human cells. The invention provides isolated IKK-β hybridization probes and primers capable of specifically hybridizing with the disclosed IKK-β genes, IKK-β-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.

    CYP7 PROMOTER-BINDING FACTORS
    5.
    发明公开
    CYP7 PROMOTER-BINDING FACTORS 审中-公开
    BINDENDE FAKTOREN DES PROMOTORS CYP7

    公开(公告)号：EP1036094A4

    公开(公告)日：2004-06-09

    申请号：EP98960807

    申请日：1998-12-08

    申请人： TULARIK INC ,  SUMITOMO PHARMA

    发明人： SHAN BEI ,  NITTA MASAHIRO

    IPC分类号： A61K38/00 ,  C07H21/04 ,  C07K14/47 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/53 ,  C12N15/12

    CPC分类号： C07K14/4705 ,  A61K38/00

    摘要： The invention provides methods and compositions relating to CPF proteins which regulate transcriptional activation, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed CPF encoding nucleic acids or purified from human cells. The invention provides isolated CPF hybridization probes and primers capable of specifically hybridizing with the disclosed CPF genes, CPF-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.

    摘要翻译： 本发明提供了与调节转录激活的CPF蛋白相关的方法和组合物以及相关的核酸。 可以从所公开的编码CPF的核酸的转化宿主细胞重组产生多肽或从人细胞中纯化多肽。 本发明提供了能够与公开的CPF基因，CPF特异性结合剂如特异性抗体特异性杂交的分离的CPF杂交探针和引物，以及在诊断，治疗和生物制药工业中制备和使用该主题组合物的方法。

    ARYLSULFONANILIDE PHOSPHATES
    6.
    发明授权
    ARYLSULFONANILIDE PHOSPHATES 有权
    ARYLSULFONANILID磷酸

    公开(公告)号：EP1090014B1

    公开(公告)日：2003-09-03

    申请号：EP99928777.4

    申请日：1999-06-16

    申请人： Tularik Inc.

    发明人： HOUZE, Jonathan, B.

    IPC分类号： C07F9/12 ,  A61K31/66 ,  C07F9/6506 ,  C07F9/655

    CPC分类号： C07F9/65517 ,  C07F9/12 ,  C07F9/65068

    摘要： The invention provides compounds, compositions and methods relating to novel arylsulfonanilide derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular restenosis, infections, atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents.

    A HIGH-THROUGHPUT SCREENING ASSAY FOR INHIBITORS OF NUCLEIC ACID POLYMERASES
    9.
    发明公开
    A HIGH-THROUGHPUT SCREENING ASSAY FOR INHIBITORS OF NUCLEIC ACID POLYMERASES 失效
    测试方法对于核酸聚合酶高通量抑制剂

    公开(公告)号：EP0793730A4

    公开(公告)日：2002-04-17

    申请号：EP95942477

    申请日：1995-11-22

    申请人： TULARIK INC

    发明人： LAMARCO KELLY ,  STRULOVICI BERTA ,  WU PENGGUANG

    IPC分类号： C12M1/34 ,  B01L3/00 ,  C12N15/09 ,  C12Q1/68

    CPC分类号： B01L3/50255 ,  C12Q1/68

    摘要： The invention provides promoter specific and promoter non-specific screening assays for identifying an inhibitor of a pathogenic nucleic acid polymerase activity, e.g., an RNA polymerase derived from a phatogenic infectious organism such as a bacterium, protozoan or fungus. Generally, the methods involve forming a mixture of nucleotide, a polynucleotide template, a pathogenic polymerase, and a candidate inhibitor of polymerase activity, where at least one of the nucleotide comprises a detectable label. In a preferred embodiment, a membrane apparatus (10) having two filters extending transversely across a well, and positioned between the top, tube containing half (11) of the apparatus (10) and the bottom, drip director containing half (15) of the apparatus (10). The top filter (13) is initially hydrophobic and capable of retaining liquid media and is rendered water permeable by contacting it with an organic solvent. The bottom filter (14) is hydrophilic water permeable and efficiently passes liquid media while retaining micro-beads during vacuum filtration.

    PPAR-GAMMA MODULATORS
    10.
    发明公开
    PPAR-GAMMA MODULATORS 有权
    PPAR-γ调节剂

    公开(公告)号：EP1053227A1

    公开(公告)日：2000-11-22

    申请号：EP99901492.1

    申请日：1999-01-20

    申请人： TULARIK, INC.

    发明人： DE LA BROUSE-ELWOOD, Fabienne ,  JAEN, Juan, C. ,  MCGEE, Lawrence, R. ,  MIAO, Shi-Chang ,  RUBENSTEIN, Steven, Marc ,  CHEN, Jin-Long ,  CUSHING, Timothy, D. ,  FLYGARE, John, A. ,  HOUZE, Jonathan, B. ,  KEARNEY, Patrick, C.

    IPC分类号： C07D213/65 ,  A61K31/435 ,  C07D239/34 ,  C07D213/643 ,  C07D233/70 ,  C07D413/12

    CPC分类号： C07D213/70 ,  C07C311/21 ,  C07D213/65 ,  C07D215/20 ,  C07D217/04 ,  C07D405/12

    摘要： Modulators of PPARη activity are provided having formula (I): in which the symbol Ar represents an aryl group; the letter X represents a divalent linkage selected from the group consisting of =C1-C6alkylene, -(C1-C6)alkylenoxy, -O-, -C(O)-, -N(R11)-, -N(R11)C(O)-, -S(O)¿k?- and a single bond, in which R?11¿ is a member selected from the group consisting of hydrogen, alkyl, heteroalkyl, and arylalkyl and the subscript k is an integer of from 0 to 2. The letter Y, in formula (I) represents a divalent linkage selected from the group consisting of alkylene, -O-, -C(O)-, -N(R12)-S(O)¿m?-, -N(R?13¿)-S(O)¿m-N(R?13)-, -N(R12)C(O)-, -S(O)¿n?-, a single bond, and combinations thereof in which R?12 and R13¿ are members independently selected from the group consisting of hydrogen, alkyl, heteroalkyl and arylalkyl; and the subscripts m and n independently integers of from 0 to 2. The symbol R1 represents a member selected from the group consisting of hydrogen, alkyl, heteroalkyl, aryl, arylalkyl, -CO¿2R?14, -CO(R)14, -C(O)NR15R16, -S(O)¿p-R?14, -S(O)¿q?-NR?15R16¿, -O-C(O)-OR17, -O-C(O)-R17, -O-C(O)-NR?15R16, -N(R14¿)-C(O)-NR?15R16, -N(R14¿)-C(O)-R17 and -N(R14)-C(O)-OR17, in which R14 is a member selected from the group consisting of hydrogen, alkyl, heteroalkyl, aryl and arylalkyl, and R?15 and R16¿ are members independently selected from the group consisting of hydrogen, alkyl, heteroalkyl, aryl and arylalkyl, or taken together with the nitrogen to which each is attached from a 5-, 6- or 7-membered ring. The symbol R17 represents a member selected from the group consisting of alkyl, heteroalkyl, aryl and arylalkyl. Additionally, for the R1 groups described above, the subscript p is an integer of from 0 to 3, and the subscript q is an integer of from 1 to 2. The symbol R2 represents a member selected from the group consisting of alkyl, heteroalkyl, aryl and arylalkyl. In another aspect, the present invention provides compounds of formula (I), as well as pharmaceutical compositions containing the compounds described above for the treatment of conditions such as type II diabetes and obesity.